Post-earnings recap
Reported
Tue, May 7, 2019
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
50%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Celldex Therapeutics reported a larger-than-expected loss in EPS, which contributed to a decline in stock price by 3.03%. The lack of revenue information and absence of guidance may raise concerns among investors about the company's future performance. The management's defensive tone suggests they are facing challenges that could impact their financial outlook.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-1.40 | N/A | -46.49% |
| Revenue | N/A | N/A | N/A |
Management expressed concerns about the current financial performance. They highlighted ongoing challenges without providing clear guidance for future quarters.
Management did not provide specific revenue guidance for the upcoming quarters.
The company acknowledged challenges in achieving profitability in the near term.